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chromatography-mass spectrometry; ITC, isothermal titration calorimetry; Preseg, 
presegetalin. Amino acids from PCY1 are referred to with one letter amino acid code, 
while amino acids from the peptide substrates are referred to with three letter amino 
acid code.  
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Abstract 
Cyclic ribosomally derived peptides possess diverse bioactivities and are currently of 
major interest in drug development. However, it can be chemically challenging to 
synthesize these molecules, hindering the diversification and testing of cyclic peptide 
leads. Enzymes used in vitro offer a solution to this, however peptide macrocyclization 
remains the bottleneck. PCY1, involved in the biosynthesis of plant orbitides, belongs 
to the class of prolyl oligopeptidases and natively displays substrate promiscuity. PCY1 
is a promising candidate for in vitro utilization but its substrates require an 11 to 16 
residue C-terminal recognition tail. We have characterized PCY1 both kinetically and 
structurally with multiple substrate complexes revealing for the molecular basis of 
recognition and catalysis. Using these insights, we have identified a three residue C-
terminal extension that replaces the natural recognition tail permitting PCY1 to operate 
on synthetic substrates. We demonstrate that PCY1 can macrocyclize a variety of 
substrates with this short tail, including unnatural amino acids and non-amino acids, 
highlighting PCY1’s potential in biocatalysis. 
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Introduction 
The class of natural products represented by ribosomally synthesized and post-
translationally modified peptides (RiPPs) are of particular interest as novel 
therapeutics.1 Several macrocyclic compounds including cyclic RiPPs are orally active 
despite the fact that they are in disagreement with Lipinskis’ Rule of Five.2 This 
behavior has lead to the term ‘beyond rule of five’ to describe peptide macrocycles.3 
The activity and utility of macrocyclic peptides arises from their increased stability 
(both chemically and to protease degradation), rigidity and hydrophobicity when 
compared to their linear peptide counterparts.4 Yet, analogously to linear peptides, 
macrocyclic peptides can encode complex structural and chemical information and thus 
may be particularly suitable to tackle difficult targets such as protein-protein 
interactions, which are traditionally challenging to target using small molecules.1 The 
de novo chemical synthesis of macrocyclic peptides is well known but has some 
disadvantages such as the requirement of multiple steps and the optimization of 
conditions necessary for the ring closing reaction for each peptide variant.5,6 Moreover, 
when the active macrocycle is highly modified, as many cyanobactins are, their 
synthesis is not considered practical.5 Biotechnology provides an alternative approach 
utilizing enzymes entirely in vivo or in vitro. The enzymes involved in RiPPs 
biosynthesis are particularly attractive as these natural products are genetically 
encoded, and the enzymes involved are able to carry out highly specific modifications 
while operating with a very broad substrate range. This allows enzyme activities from 
different pathways and organisms to be combined.7  
 
Cyanobactins possess a wide range of desirable and valuable bioactivities including 
anti-cancer (cytostatic and cytotoxic), antifouling, immunomodulating and 
antineoplastic.8 An understanding of the cyanobactin biosynthetic machinery has 
underpinned the production of a wide range of novel cyanobactins in vivo9,10 and in 
vitro.11–14 Whilst in vivo approaches - sometimes termed ‘cell factory’ - hold the 
advantage of simplicity, in vitro technologies have the unique capacity of harnessing 
the power and diversity of chemical synthesis. This means that not only multiple 
different non-natural amino acids can easily be accommodated, but hybrid molecules 
(peptide and non-peptide) that are impossible to be produced in vivo can be generated.13 
To date, the majority of reports of in vitro macrocyclization have used the macrocyclase 
domain from the patellamide pathway (PatGmac). Although extremely promiscuous, 
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the enzyme has extremely slow catalytic rates in vitro, a major drawback that limits its 
application at large scale.15 A fast and promiscuous macrocyclase enzyme is thus highly 
desirable. Of the macrocyclases known to date, PatGmac (and other members of its 
family), the prolyl oligopeptidases (POPs) from Basidiomycete mushrooms (AbPOPB 
and GmPOPB),16 and PCY1 from the plant Saponaria vaccaria (syn. Saponaria 
hispanica)17 are known to catalyze the formation of small macrocycles (containing 
between 5 and 9 amino acids). Although butelase 1 from Clitoria ternatea is extremely 
fast18 and highly versatile,19 it does not produce small ring macrocycles efficiently,20 
and a similar situation occurs with the MdnB from Microcystis aeruginosa (ATP-grasp 
superfamily).21 Further limiting the widespread use of butelase 1 is the difficulty of its 
overexpression in E. coli18,19 and limited solubility (partially overcome by engineering 
but with decreased activity).22 
The POP class of macrocyclases has been underexplored in terms of biocatalysis. 
GmPOPB has been kinetically and structurally characterized, and although it possesses 
fast reaction rates, it displays narrow substrate scope.16,23,24 PCY1, the macrocyclase in 
the biosynthesis of a range of plant cyclic peptides known as segetalins, has been shown 
to be a naturally promiscuous enzyme capable to generate 5 to 9 residue segetalins, 
although the reported turnover rates are slow.17 A two-step biosynthetic pathway for 
segetalins has been proposed, starting from a precursor peptide in which the core 
peptide is flanked by both a leader and tail peptide.17 Firstly a 10 amino acid N-terminal 
sequence (termed the leader in RiPPs biosynthesis)25 is removed by an uncharacterized 
peptidase to give the presegetalin, then PCY1 catalyzes peptide bond formation to yield 
the corresponding macrocyclic peptide and cleaved C-terminal peptide (Figure 1a). 
Two PCY1 complex structures have been published, the substrate’s core sequence 
organization within PCY1’s active site were not resolved, leaving unanswered 
questions about peptide recognition and macrocyclization.26 
 
Here we report the first apo structure of PCY1 as well as complex structures with 
natural substrates resolving substrate core within the active site for the first time. 
Combining structure, kinetics and thermodynamics, we have discerned the rules 
governing substrate recognition. Based on these rules we demonstrate the enzyme’s 
will macrocyclize efficiently with a three residue C-terminal recognition tail. Using this 
tail we show PCY1 operate on peptides including a peptide alkyl chain hybrid, peptides 
containing N-methylated peptide bond as well as thiazoline containing peptides. PCY1 
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is an attractive tool for in vitro biosynthesis of diverse cyclic peptides. 
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Results and Discussion 
Mechanism of PCY1 
PCY1 operates via an acyl enzyme intermediate in a classical serine protease 
mechanism,27 with the N-terminus of the peptide rather than water acting as the 
nucleophile. 26 The PatGmac macrocyclase also operates by this mechanism,28 although 
possessing an entirely different fold. The putative catalytic triad (D653, H695 and 
S562) is located in the peptide-binding site of PCY1. The catalytic serine and histidine 
are further apart than is observed for the triad in other POPs, although a similar ‘non-
optimal’ arrangement is present in GmPOPB.24 Activity tests using PresegB1 as a 
substrate for macrocyclization confirmed that PCY1 mutants S562A and H695A were 
inactive (Figure S1). 
Kinetic characterization of PCY1 
Barber et al. described PCY1 to have a turnover number of ~ 1 h-1 for PresegA1.17 We 
evaluated the enzyme produced heterologously in E. coli by LC/MS-based time course 
experiments macrocyclizing 200 µM of PresegA1, PresegB1 or PresegF1 with 3.6 µM 
PCY1. These substrates were chosen as they produce 6, 5 and 9 residue macrocycles, 
respectively, show variability in the length of the C-terminal tail sequence, and have a 
different C-terminal core residue (proline in PresegF1, alanine in the other two) (Figure 
1b, Figure S2). PresegB1 was completely macrocyclized in ~ 30 min, PresegA1 in ~ 50 
min and PresegF1 in > 3 h (Figure 2a). We chose to investigate the slowest and fastest 
substrate by steady-state kinetics using an LC/MS assay and UV280 nm quantification. 
This resulted in a kcat/Km value of 830,000 M
-1 s-1 for PresegB1 (Figure 2c and Table 
1), which is not only considered above ‘average’ for a typical enzyme29 but is also 
larger than the efficiency using the second-order rate constant of butelase 1 from 
Clitoria ternatea (542,000 M-1 s-1), the fastest macrocyclase described to date.18 The 
UV280 nm detection at low substrate concentrations and thus accurate determination of 
Km was problematic, especially for PresegF1, which lacks a tryptophan in its sequence. 
We explored steady-state kinetics with single injection kinetic ITC for PresegB1 
(Figure 2d and Table 1) and this allowed more accurate determination of Km (0.25 ± 
0.01 µM). Under the ITC conditions, the measured kcat (0.14 ± 0.01 s
-1) was a factor of 
three lower than the LC/MS derived value. However, to obtain kinetic parameters for 
PresegF1, a different approach was required since single injection kinetic ITC only 
showed a small heat change. Therefore, we employed an LC/MS assay followed by 
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quantification using mass ion counts, relying on a calibration curve employing the 
cyclic peptide product as a standard (Figure 2b). This approach gave a Km of 2.40 ± 
0.51 µM and kcat of 0.12 ± 0.01 s
-1 for PresegF1. These kinetic parameters line up with 
steady-state kinetics performed using PresegA126, and show that the difference in 
efficiency that we observed in the time course experiments is due to large differences 
in Km rather than in the turnover rate. 
 
Crystallization of PCY1 
PCY1 has been predicted (through homology modelling using a porcine muscle prolyl 
oligopeptidase (POP) structure)17 and shown via X-ray crystallography studies to 
belong to the S9 protease family26, displaying the overall architecture of the POP family 
comprising an /- hydrolase domain and a seven bladed -propeller (Figure S3). The 
structures of PCY1 bound to PresegA1 and to the covalent small molecule inhibitor z-
proline-prolinal (ZPP) have been published but disorder meant only the recognition of 
the C-terminal NASAPV motif (conserved in PCY1 substrates17 Figure S2) was 
visualised.26 Our 2.55 Å PCY1 apo structure with a cacodylate molecule at the active 
site is similar (rmsd: 0.88 Å over 4,853 atoms; Table S1) to the previously reported 
PCY1 complex adjacent to the active site comprising S562, H696 and D563 (Figure 
S4). Cacodylate is coordinated through hydrogen bonds by the side chain hydroxyl 
group of Y481 and the amide of N563; both residues have been proposed to form the 
oxyanion hole in the POP-family of enzymes (Figure S5).30,26 The PCY1 structures all 
have a closed conformation in contrast to the open apo structure of GmPOPB (Figure 
S3), a structural homologue in the POP family with low sequence identity.24 Although 
co-complexes were described for GmPOPB the core peptide was not visualized.24 To 
obtain more structural insight into substrate recognition for the POP macrocyclase 
family we explored other substrates for co-crystallisation with PCY1.26 
 
Substrate recognition 
We determined complex crystal structures of PCY1:S562A bound to PresegA1 (2.0 Å), 
PresegB1 (2.17 Å) and PresegF1 (1.86 Å) (Table S2). We did not observe continuous 
electron density spanning the entire length of the peptide substrate in any of the 
structures solved (Figure 3a). In all three complexes however, the C-terminal peptide 
(NASA(S)PV) is clearly visible and adopts the same structure (Figure 3b,c and Figure 
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S6), seen in in previously published PCY1 complex structures with PresegA1 (Figure 
S6).26 In the PresegF1 complex, the highest resolution structure, the carboxylic acid 
group of the substrate’s C-terminus V25 makes hydrogen bonds to the backbone amide 
and side chain of S495 as well as the side chain of S493. The carboxyl group is 
positioned at the N-terminal end of the helix thus interacting with the helical dipole 
(Figure 3b,c). In the substrate, the side chains of Val25, Pro24, Ala23, and Ala21 make 
only a few van der Waal contacts with the protein, while the main chain of Ala21 makes 
hydrogen bonds with the protein. Both the main and side chain of Ser22 and Asn20 
make either direct or water bridged hydrogen bonds. 
 
In the PresegA1 complex, no other residues could be modeled, as previously observed 
by Chekan et al.26 However, in PresegF1 and PresegB1 complex structures, it was 
possible to model the core peptide in at least one of the subunits within the asymmetric 
unit, although the intervening residues that connect core to the tail were not ordered. In 
PresegF1, we visualized Phe1 to Gln11 (Figure 3a) but not Thr12 to Met19. In the other 
three subunits, electron density for the N-terminal region of core peptide has been less 
well defined, suggesting there could be multiple binding conformations. In the best-
ordered subunit, one face of the proline (Pro9) ring in the substrate stacks against W603 
whilst the edge of the ring interacts with F484. The Leu8-Pro9 peptide bond (P2-P1) 
adopts a trans configuration. The remainder of the core peptide makes a small number 
of hydrogen bonds and van der Waal interactions (Figure S7). The scissile bond P1-P1 
(Pro9-Ile10, Figure S8) is positioned such that the modeling of the hydroxyl at S562A 
results in the distance and orientation expected for the formation of the acyl enzyme 
intermediate (Figure 3d), with the Y481 and N563 acting to stabilize the negative 
charge (Figure S9). The chemically sensible positioning of the scissile bond at the 
active site validates the relevance of the structure. The P1 side chain (Ile10) sits in a 
hydrophobic cleft making contacts with the side chains of Y481 and I466 (Figure S8). 
The amino terminus of the substrate is over 20 Å from the scissile bond, requiring 
extensive conformational flexibility from the substrate for macrocyclization to occur. 
 
A comparison between complex structures of PCY1-S562A bound to PresegF1 and 
GmPOPB-S577A bound to a 35 amino acid substrate (GmAMA1) reveal that although 
the overall protein architecture is remarkably similar, significant differences exist 
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between the location of the peptide ligand, and positioning of specific regions of each 
peptide (Figure S10). In GmPOPB, the entire peptide tail or recognition sequence 
-
propeller domain. In contrast, in PCY1 the recognition sequence is not inserted into the 
propeller domain, and only the last C-terminal residues can be observed, demonstrating 
greater flexibility in the peptide region that follows the core peptide, different to 
GmPOPB. The core sequence of the macrocyclization substrate was not experimentally 
observed in GmPOPB complexes (pdb codes 5N4B and 5N4D).24 
 
In the PresegB1 PCY1 complex, the P2-P1-P1 residues (Trp4, Ala5 and Phe6, Figure 
S8 and S11) adopt an identical main chain conformation, make similar interactions as 
PresegF1, and are thus positioned for attack by S562. However, the remaining three 
residues of the core peptide have a different and more ring-like conformation than 
PresegF1 and as a result the N-terminus is only 11 Å away from the scissile bond 
(Figure S12). Thus, PresegB1 needs less re-organization than PresegF1 and this may 
underlie the difference in their macrocyclization turnover rates. Comparing the PCY1 
structures in the PresegB1 and PresegF1 complexes reveals the structures are very 
similar (root mean square deviation 0.8 Å over 707 C atoms). The most notable 
change occurs in the main chain at Y696 which, in the PresegF1 complex, has flipped 
so that the side chain points into the structure core, and as consequence the loop at E154 
has moved to accommodate it (Figure S13). In PresegB1, the residue adopts a different 
rotamer but the position of the main chain is unchanged. The change at Y696 appears 
necessary to avoid a clash between this residue and the core of the substrate. In both 
complexes, R655 makes hydrogen bonds to the substrate in the P2-P1-P1 region 
although the precise interactions are different. Informed by the crystal structures, we 
constructed mutants S493A, S495A, Y696G, R655A and W603A using the reaction 
with PresgB1 as a test substrate. The relative activities of S495A, S493A, R696G, and 
R655A were decreased by half, while W603A and H695Q showed around 10% relative 
activity, and H695A was inactive (Figure S1). No variant resulted in an increase in 
proteolytic (as opposed to macrocyclase) activity.  
 
To further investigate substrate binding, we performed ITC experiments using 
PresegA1, PresegB1, PresegD1 and PresegF1 with PCY1:S562A. All four peptides 
  11 
showed tight binding with Kd values around 200 nM (Figure 4a, Table 2 and Figure 
S14). The major contribution to binding of all tested peptides is enthalpic rather than 
entropic (Figure 4b), pointing towards interactions between protein and substrate rather 
than exclusion of water. The C-terminal tail of PresegA1 was previously reported to be 
essential for activity.17 The only conserved amino acids in all natural substrates are the 
C-terminal six residues (NASA(S)PV) (Figure S2). The peptide NASAPV binds with 
a Kd of only 25 µM suggesting that this region although conserved does not dominate 
binding (Table 2, Figure S14). We measured the binding of PresegA1-NH2 (an amide 
rather than carboxylic acid at C-terminus) to PCY1:S562A and observed a ~70-fold 
decrease of affinity (Kd: 12.1 µM) (Table 2, Figure 4). 
 
Structural data point to a key role for W603 in positioning the substrate with the correct 
geometry for attack by S562. Unlike the PatGmac class of macrocyclase,27 PCY1 does 
not require a proline residue or cis-like geometry for activity. Instead, we propose the 
site of macroyclization is controlled by the nature of the residues at P1 and P1 of the 
substrate. The structure shows that PCY1 residues W603, F484, Y607, and V558 would 
clash with the amino acids that have two non-hydrogen substituents at C (Val, Ile, 
Thr) or larger. Although serine cannot be ruled out on purely steric grounds, the 
hydrophobic nature of the environment favors proline or alanine. The binding site at 
P1 is hydrophobic but requires larger side chains such Ile, Phe, or Leu to make 
interactions with the protein (Figure S8). This sequence pattern is found at the point of 
scission for all known substrates for PCY1 (Figure S2c). The Kd for DNASAPV (9.6 
µM) and NASAPV (25.2 µM) with PCY1:S562A were larger than observed for full 
length substrate (Table 2 and Figure S14). A peptide substrate without the C-terminus 
(PresegF1-truncated, FSASYSSKPIQT) was evaluated although its Kd could not be 
accurately measured but was estimated to ~ 0.6 mM (poor peptide solubility and weak 
binding prevent more accurate measurement) (Table 2 and Figure S14). The peptide 
that links P2-P1-P1 of the core and the C-terminus is highly variable in sequence and 
in length (Figures 1b and S2) consistent with this region acting as a flexible linker rather 
than a recognition element. Whilst the intact peptide binds very tightly, these two 
regions on their own bind more weakly, suggesting a model where affinity is generated 
by linking binding sites (conceptually analogous to the chelate effect).31 
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Exploring substrate promiscuity 
It is known that PCY1 is tolerant of significant changes in sequence within the core 
peptide and competent to make macrocycles as short as five and as large as nine 
residues.17 We tested the ability of PCY1 to make larger macrocycles by extending the 
core sequence of PresegF1 by one amino acid and PCY1 was able to macrocyclize this 
substrate (Figure S15 and S16). This extends the full range of relevant peptide 
macrocycles that PCY1 makes to include the upper limit (1000 Da) for ‘beyond rule of 
five’ macrocycles.32 However, the requirement for a long disposable C-terminus is a 
major drawback of the use of PCY1. The molecular recognition of substrate peptide by 
PCY1 prompted us to devise substrates with a short C-terminal extension replacing the 
native recognition sequence. We analyzed reactions of a peptide containing 
FSASYSSKP (F1 core) with different truncated recognition sequences derived from 
PresegB1 or PresegF1 added C-terminal to the core. In both PresegB1 and PresegF1 a 
three residue tail gave optimal results (Figure S17) but a diverse set of extensions 
(sequence and length) supported catalysis. PresegB1 derived recognition sequences in 
general yielded more SegF overnight in comparison to the PresegF1 derived 
recognition sequences. Steady-state kinetic analysis of the variants revealed FQA is the 
superior truncated recognition sequence over IQT with a ~ 17x larger second-order rate 
constant, but both show synthetically useful kcat and Km values (Table 1 and Figure 
S17). Although GmPOPB can also process short tailed substrates,24 it is slower (kcat at 
20 °C using a shorter substrate is 0.010 s-1), intolerant of changes in core length and 
restricted in sequence acceptance. We tested the core sequence VTACITWP (related to 
the natural substrate of PatGmac and unrelated to PCY1 natural substrates) with both 
short recognition sequences: FQA, and IQT. The peptides (250 µM) were processed 
with 0.5 µM PCY1 and compared to a 25 µM PatGmac reaction of 
VTACITWPAYDGE (AYDGE contains the PatGmac recognition sequence). After 90 
minutes, PCY1 had turned over ~29 x and ~11 x more substrate for the FQA and IQT 
variants as analyzed by LC/MS (Figure S18), respectively than the PatGmac reaction 
(PatGmac was at 50-fold higher concentration). PCY1 therefore outperforms PatGmac 
on an eight-residue core sequence similar to PatGmac’s own substrate. Although known 
to process a wide range of amino acids within the core peptide, the tolerance of PCY1 
for non-natural amino acids is unknown. Capitalizing on our discovery of truncated 
substrates, we explored the scope of PCY1 with such shortened substrates containing 
unnatural and modified amino acids. PresegF1 core peptide modified with an amino 
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octanoic acid (FSA-8Aoc-FP) and VGAG-8Aoc-FPIQT (derived from a known 
PatGmac substrate) (Figure S19-S21), MALDI spectrum shows an approximate 50% 
conversion rate overnight for the first peptide FSA-8AOc-SKPIQT with only traces of 
the linear-cleavage peptide alongside the cyclic peptide (Figure S19), while the other 
precursor peptide VGAG-8Aoc-FPIQT is almost entirely converted overnight to a 
mixture of the corresponding cyclic peptide and linear-cleavage peptide (Figure S20). 
The same reaction with the highly promiscuous PatGmac would have required 60 times 
the amount of enzyme and an average of 20 days for completion. Nonetheless, PatGmac 
usually gives rise to either exclusively linear-cleavage peptide (especially for shorter 
peptides) or none at all, as was the case for the VGAG-8Aoc-FP peptide.13 Additionally, 
we showed that PCY1 can macrocyclize FSmASYSSKPIQT and FSmASYSSKPFQA 
(where mA is N-methylated alanine) and produce cyclic FSmASYSSKP (Figure S22 and 
S23). N-methylated peptidic drugs are known to cross cell membranes more efficiently 
than compounds lacking this chemical feature. Taken together, our data show that the 
processing activity of PCY1 is not simply limited to the canonical amino acids within 
the core. PCY1 failed to process a proline-rich PresegF1 variant yielding only a 
hydrolysis product (Figure S24). Such proline-rich peptides are also extremely poor 
substrates for PatGmac, an observation attributed to the conformational rigidity 
imposed by multiple proline residues.28 Using LynDfus., an engineered heterocyclase 
enzyme,33 we converted VTACITWPIQT into VTAThnITWPIQT (Thn: thiazoline) in 
situ to explore sensitivity to heterocycles which will impose conformational 
restrictions. Incubation with 1 µM PCY1 produced both macrocyclic and hydrolyzed 
linear peptides (Figure S25-S26), yielding 10.9 µM Thn containing macrocycle after ~ 
20 h incubation, representing a 4.4 % conversion. Although a conversion this low is not 
synthetically useful, based on well established methods of optimization of enzyme 
activity including directed evolution this turnover represents a starting point for future 
improvement.34 Further investigations are being conducted to study variants of the 
mutated enzyme and the reaction conditions in order to improve the synthesis of such 
hybrid cyclic peptides. 
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Summary 
The importance of peptidic and amino acid-containing macrocycles in medicine is now 
clear. Robust synthetic approaches for these molecules, which can combine synthetic 
diversity with the ability of enzymes to catalyze challenging chemical steps, are highly 
desirable. Here we have reported the characterization of PCY1, a macrocyclase from 
plant. We show substrate recognition occurs in two distinct patches of the substrate, 
joined by a flexible linker, which underpins the promiscuity of PCY1. Based on 
understanding substrate recognition, we have demonstrated that the enzyme can utilize 
simpler synthetically accessible substrates with a short C-terminal extension at a 
synthetically useful rate. PCY1 can process hybrid molecules than are not solely 
composed of canonical amino acids, suggesting PCY1 could represent a valuable 
synthetic tool. 
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Materials and Methods 
Materials 
All reagents, but peptides, were purchased from Sigma-Aldrich, unless stated 
otherwise. All peptides were commercially obtained from Biosynthesis, unless 
otherwise stated. HPLC grade acetonitrile (MeCN) was purchased from Fisher. 
Aqueous buffers and aqueous mobile-phases for HPLC were prepared using water 
purified with an Elga® Purelab® Milli-Q water purification system (purified to 18.2 
MΩ.cm) and filtered over 0.45 μm filters.  
 
Cloning, expression and protein purification 
Codon optimized full-length PCY1 (Saponaria vaccaria) including an N-terminal His6-
tag and a cleavable Tobacco etch virus (TEV) protease site (sequence ENLYFQG, 
cleaving between Q and G) encoded in pJ414 plasmid was purchased from DNA2.0. 
Over-expression of PCY1 was performed in E. coli BL21 (DE3) grown in LB media. 
Cultures were inoculated and grown at 37 °C until OD600 nm: ~ 0.6, after which the 
temperature was lowered to 16 °C and protein expression was induced with 0.5 mM 
IPTG (final concentration, Generon). Bacteria were grown for 20 h at 16 °C, and cells 
were harvested by centrifugation at 8,983g for 10 min at 4 °C (Avanti J-26S, rotor JLA-
8.1000, New Brunswick Scientific). Wet cell pellets were stored at -80 °C until protein 
purification. Cell pellets were resuspended in buffer A (50 mM HEPES, 300 mM NaCl, 
10 % (v/v) glycerol, 3 mM βME (Fischer Chemical), pH 8.0) supplemented with 
EDTA-free protease inhibitor tablets (Roche) and 0.4 mg DNase I from bovine 
pancreas per g wet cells, at 4 °C. Cells were disrupted by double passage through a cell 
disruptor (Constant Systems Ltd) at 30 kPSI. The lysate was subsequently cleared via 
centrifugation at 43,667g at 4 °C for 20 min (rotor JA 25.50, New Brunswick 
Scientific). The cleared lysate was loaded onto a 5 mL Co HiTrap TALON (GE 
Healthcare), pre-equilibrated in buffer A. Protein was eluted in buffer B (50 mM 
HEPES, 300 mM NaCl, 10 % (v/v) glycerol, 250 mM imidazole, 3 mM βME, pH 8.0). 
TEV protease was added to the eluted sample (1 mg per 30 mg of eluted protein) and 
this mixture was dialyzed into 1 L of buffer A at 4 °C overnight. The dialyzed sample 
was applied onto a 5 mL Co HiTrap TALON, equilibrated in buffer C (50 mM HEPES, 
300 mM NaCl, 10 % (v/v) glycerol, 3 mM βME, pH 8.0). The flow-through of this 
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reverse Ni-affinity chromatography step was pooled and dialyzed into 1 L of buffer D 
(50 mM HEPES, 5 mM NaCl, 10 (v/v) glycerol, 3 mM βME, pH 8.0) at 4 °C for 1 h 
and subsequently subjected to anion exchange chromatography using a 5 mL HiTrap 
Q-FF column (GE Healthcare) and a gradient of buffer D and E (50 mM HEPES, 500 
mM NaCl, 10 % (v/v) glycerol, 3 mM βME, pH 8.0). Eluted samples containing PCY1 
(verified by SDS-PAGE) were pooled, concentrated and further purified using size-
exclusion chromatography (HiLoad 16/600 Superdex 200 pg, GE Healthcare) pre-
equilibrated in buffer F (50 mM HEPES, 150 mM NaCl, 10 % (v/v) glycerol, 1 mM 
TCEP (tris(2-carboxyethyl)phosphate), pH 8.0). Purity and identity of final protein 
sample were confirmed by SDS-PAGE and mass spectrometry. 
 
Site directed mutagenesis 
Site directed mutagenesis was performed using an overlaying mutation carrying primer 
pair (IDT) of ~30 nucleotides employing Pfu polymerase (Thermo Scientific) for 
amplification (95 °C 3 min initial denaturation; 15 x 95 °C 30s denaturation followed 
by Tm-5 °C 45 s annealing and 72 °C 2min/kb extension, 68 °C 20 min final extension), 
according to manufacturer instructions. The amplification product was DpnI digested 
(Thermo Scientific, according to manufacturer’s instructions), and used for 
transformation of E. coli DH5α. Sequencing was performed by Eurofins. 
 
Crystallization, data collection and crystallographic analysis 
PCY1 and PCY1:S562A crystals (apo and as complexes) were obtained from hanging 
drop vapor diffusion crystallization experiments with 500 µL reservoir solution and 2 
µL drops (1:1 protein/precipitant ratio). When additive screens were performed, 0.2 µL 
of additive screen (Hampton Research) was added to the 2 µL crystallization drop. 
Crystals were harvested, cryo protected and subsequently flash frozen in liquid 
nitrogen. All data sets were collected at Diamond Light Source (UK).  
 
Apo PCY1 was crystallized at 12.2 mg/mL in 33% (w/v) PEG 2000, 113.75 mM Mg 
formate and 0.1 M Na cacodylate pH 7.0. For cryo protection 10% (v/v) glycerol were 
added to reservoir solution. Data was collected at 100 K at beamline i04. Data was 
processed using the processing pipeline xia2 3d.35,36 PCY1:S562A complex with 
PresegA1 was crystallized at 13.3 mg/mL with 163 µM PresegA1 in 28% (w/v) PEG 
5000 MME, 140 mM Mg acetate tetrahydrate and 0.1 M Tris pH 7.5. For cryo 
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protection 7% (v/v) glycerol were added to reservoir solution. Data was collected at 
100 K at beamline i04-1. Data was processed using the processing pipeline xia2 
3dii.35,37 PCY1:S562A complex with PresegB1 was crystallized at 13.3 mg/mL with 
163 µM PresegB1 in 34.5% (w/v) PEG 3350 and 70 mM Mg sulfate. For cryo 
protection 5 % (v/v) glycerol were added to reservoir solution. Data was collected at 
100 K at beamline i04-1. Data was processed using the processing pipeline xia2 3d.35,36 
PCY1:S562A complex with PresegF1 was crystallized at 13.0 mg/mL with 161.3 µM 
PresegB1 in 27% (w/v) PEG 3350, 100 mM Calcium chloride and 0.1 M Bis-Tris at 
pH 6.5. For cryo protection 10% (v/v) glycerol were added to reservoir solution. Data 
was collected at 100 K at beamline i24. Data processing was performed with xia2 
3dii.35,37 Data processing, structure solution and structure refinement were performed 
using the CCP4 software suite.38 Apo PCY1 structure was solved using molecular 
replacement using PHASER and 1QFS as search model (α/β-hydrolase and β-propeller 
domain as separated search models).39  The initial solution was then completed with 
buccaneer and manual model building and refinement of the model were performed 
using Coot and refmac5, respectively, including TLS refinement and model validation 
using MolProbity.38,40–46 For all co-complex crystal structures, apo PCY1 structure was 
used as search model. 
 
ITC studies with PCY1 variants and peptide ligands 
Equilibrium binding experiments with PCY1:S562A and different substrates were 
performed using a MicroCal PEAQ-ITC (Malvern) in buffer F (see ‘Protein 
purification’). All samples were buffer-exchanged or solubilized into buffer F and 
further diluted in the same batch of buffer F, in order to minimize buffer mismatches. 
ITC binding experiments were performed using a cell solution containing PCY1:S562A 
and a titrant solution with each peptide. All peptides were used at 200 µM except for 
presegetalin A1-NH2 (700 µM), DNASAPV and NASAPV (1.5 mM) as well as 
FSASYSSKPIQT (2 mM) . The cell contained 20 µM, 18.3 µM, 17.1 µM 15.5 µM, 
100 µM, 52.6 µM, 52.5 µM and 59.8 µM PCY1:S562A for Presegetalin A1 , B1 , D1 , 
F1 and A1-NH2, DNASAPV, NASAPV and FSASYSSKPIQT, respectively. The 
measurements were performed at a stir speed of 750 rpm at 25°C using a reference 
power of 10 µcal/s, except for A1 -NH2, DNASAPVY, NASAPV and 
FSASYSSKPIQT (5 µcal/s). A buffer titration control in which peptide was titrated 
into buffer was performed for each experiment. Data processing, fitting to a non-linear 
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one-site binding model, and data plotting was performed using MicroCal PEAQ ITC 
analysis software (Malvern). 
Single injection kinetic ITC measurements were performed using MicroCal PEAQ-ITC 
with 60 nM PCY1 in the syringe and 193 µM presegetalin B1 in the cell. To start the 
reaction, 2 µL of 9.06 µM PCY1 was injected into the cell (4 s injection time) 
containing 300 µL of 193.5 µM Presegetalin B1. The measurement was performed in 
buffer at 30 °C, at 750 rpm using a reference power of 5 µcal/s. Data processing for 
kinetic ITC measurements was performed using MicroCal PEAQ ITC analysis 
software. Data fitting and plotting were performed using Prism 6 (GraphPad Software). 
Steady-state kinetics data were fitted according to Michaelis Menten equation 
(corrected by enzyme concentration; equation (1)). 
 
𝑣i ∙ [E]t
−1 =
𝑘cat∙[𝑆]
𝐾m+[𝑆]
         (1) 
 
LC/MS assays: time courses and steady-state kinetics 
All kinetic measurements (activity tests, progress curves and initial-rate experiments) 
were performed as discontinuous assays analyzing samples via LC/MS or MALDI (10-
mer activity test). Reactions were performed in 20 mM Tris pH 8.5, 100 mM NaCl, 5 
mM DTT (for comparative time courses of PresegA1, PresegB1 and PresegF1 0.2 mg 
mL-1 BSA was included). All reactions (comparative time courses, steady state kinetics, 
PCY1 and PatGmac comparison and recognition sequence analysis) were performed at 
30 °C and at various time points 50 µL samples were quenched with 20 µL of 6 % (v/v) 
TFA. Steady-state kinetics were performed with 30 nM PCY1 for PresegB1, 0.1 µM 
PCY1 for PresegF1, 0.25 µM for FSASYSSKPIQT and 50 nM for FSASYSSKPIQT. 
Recognition sequence experiments were performed at 250 µM [substrate] and 0.5 µM 
PCY1. Assays comparing PCY1 and PatGmac were performed with 250 µM substrates 
and 0.5 µM PCY1 or 25 µM PatGmac. Reactions were quenched at different time points 
with 1.7 % TFA (final concentration), samples were spun down at 20,817g and 50 µL 
were loaded onto a ZORBAX SB-C18, 5 µm, 9.4 mm × 50 mm (Agilent) column 
connected to an Agilent LC−MS instrument (G6130B Single Quad, Agilent 
Technologies). Reactants were separated from products using a gradient from A (H2O 
with 0.1% formic acid) to 80% B (acetonitrile), at a flow rate of 1.5 mL/min for 8.75 
min. For data analysis, ion count peaks and UV absorbance peaks were integrated using 
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Agilent ChemStation software. For high resolution mass spectrometry and mass 
fragmentation of analysis of requirement of recognition sequence in presegetalins, and 
comparison between PCY1 and PatGmac, 10 µL of quenched reaction mixture was 
injected onto a ZORBAX SB-C18, 5 µm, 9.4 mm × 50 mm (Agilent) column connected 
to an UltiMate 3000 LC system (Thermo Scientific) connected to an Orbitrap Velos 
Pro MS system (Thermo Scientific). Reactants were separated from products using a 
gradient from A (H2O with 0.1% formic acid) to 95% B (acetonitrile), at a rate of 1.5 
mL/min for 12 min. For data analysis, ion count peaks were integrated using Thermo 
Xcalibur Qual browser software. For data analysis involving quantitative mass spec 
integration, calibration curves with cyclic peptide (SegF) standards (treated as reaction 
products) were performed in triplicate in order to linearly correlate ion counts to cyclic 
product concentration. SegF1 was biosynthesized using 0.5 µM PCY1 for 50 µM 
PresegF1, overnight incubation at 30 °C in reaction buffer. Reaction as quenched with 
1.7 % TFA (final concentration). Semi-preparative RP-HPLC was performed on an 
Agilent Infinity 1260 series equipped with an MWD detector using a Macherey-Nagel 
Nucleodur C18 column (10 μm x 21 x 250 mm at 21 mL/min), fractions were collected 
automatically by peak detection at the specified wavelength using an Agilent 1260 
Infinity preparative-scale fraction collector using the following chromatographic 
system: MeCN and 0.1 % aqueous TFA [95% TFA (5 min), linear gradient from 5 to 
95% of MeCN (35 min), 95% MeCN (40 min)] and UV detection at 280 nm for peak 
collection, while monitoring at the additional two wavelengths 220 and 254 nm. 
Fractions of pure SegF were combined and freeze dried before being used for the 
assays. 
Further data fitting and plotting was performed with Prism 6. Comparative time course 
measurements of PresegA1, PresegB1 and PreseF1 were fitted non-exponentially 
(equation (2)). Data for steady-state kinetics were fitted to a Michaelis Menten equation 
(corrected by enzyme concentration; equation (1)). Reactions investigating 
heterocycle-containing macrocyclic VTACITWP formation have been performed 
under different conditions: 100 mM NaCl, 100 mM TRIS pH 8.5, 5 mM DTT, 10 mM 
MgCl2 and 5 mM ATP with 250 µM VTACITWPFQA or VTACITWPIQT and 10 µM 
LynDfus. and 1 µM PCY1 (added after 19 h). Reactions were stopped via filtration 
through 30 kDa cut off VIVASPIN 500 (Sartorius) concentrators. 
 
𝑦 = 𝑦0 + 𝑎(1 − 𝑒
−𝑘∙𝑥)        (2) 
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y0: offset; k: apparent rate; a: amplitude 
Peptide analysis on the TripleTOF 5600 
Peptides were injected on an Acclaim PepMap 100 C18 100 µm × 2 cm trap and washed 
for 5 min to waste after which the trap was turned in-line with the analytical column 
(Acclaim Pepmap RSLC 75 µm × 15 cm, both ThermoFisher Scientific) using a 
nanoLC Ultra 2D plus loading pump and nanoLC as-2 autosampler (Eksigent).  
 
The analytical solvent system consisted of buffer A (2% acetonitrile, 0.1% formic acid 
in water) and buffer B (2% water, 0.1% formic acid in acetonitrile) at a flow rate of 0.3 
μl/min with the following gradient: linear 5-40% of buffer B for 6 min, linear 40-95% 
of buffer B for 3 min, isocratic 95% of buffer B for 3 min, linear 95-1% of buffer B for 
2 min and isocratic 1% solvent buffer B for 6 min for re-equilibration.  
The eluate was sprayed into a TripleTOF 5600 electrospray tandem mass spectrometer 
(ABSciex, Foster City, CA) and analyzed in Information Dependent Acquisition (IDA) 
positive ion mode. For each MS scan (m/z 150-1250) of 150ms, 20 MSMS (m/z 100-
1800) of 80 ms with 10 s dynamic exclusion were acquired. Rolling collision energy 
with a collision energy spread of 5 eV was used for fragmentation. 
 
To obtain better MSMS spectra of the peptides of interest, a product ion scan (PIS) of 
the relevant masses were analyzed. The LC condition were kept constant with an 
adjusted gradient: linear 5-40% of buffer B for 16 min, linear 40-95% of buffer B for 3 
min, isocratic 95% of buffer B for 3 min, linear 95-1% of buffer B for 2 min and 
isocratic 1% solvent buffer B for 6 min for re-equilibration. The mass spectrometer was 
operated in product ion mode with four selected masses of interest. Each MS and 
MSMS scan (m/z 100-2400) was acquired for 100ms respectively. 
 
 
In house peptide synthesis 
Automated solid-phase peptide synthesis (SPPS) was carried out on a Biotage® Syro 
Wave™ system in polypropylene (PP) syringe with a PTFE frit. Final cleavage and 
deprotection were completed manually. 
The different precursor peptides were synthesized by standard automated solid-phase 
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(SPPS) on a Chem-Matrix Rink amide resin (~ 0.5mmol/g) or a Trityl chloride resin (~ 
0.4 mmol/g) using the Fmoc strategy and Fmoc-protected amino acids. A double 
coupling strategy using a 5-fold excess with 2-(1H-benzotriazol-1-yl)-1,1,3,3,-
tetramethyluronium hexafluorophosphate (HBTU)/N,N-Diisopropylethylamine 
(DIPEA) (HBTU, 0.5M in DMF and DIPEA, 2M in NMP) and DIC/oxyma pure (DIC, 
0.5M in DMF, Oxyma, 1M in DMF) was used for all amino acids for 30 minutes at 75 
°C, except for the loading of the first amino acid on the trityl resin. In order to achieve 
that, to the resin (swelled in CH2Cl2) was added the amino acid (2 eq.) and DIPEA (4 
eq.) in CH2Cl2 and the reaction agitated at room temperature for 2 hours. The reaction 
mixture was discarded, the resin was washed and capped by the addition of MeOH and 
DIPEA in CH2Cl2 (2:1:18) for one hour at room temperature. After washing the resin, 
the peptide synthesis is completed as described. The Fmoc deprotection was done in 
20% piperidine/DMF for 12 min at rt. For the final cleavage and side chain 
deprotection, the beads (washed with CH2Cl2 and dried) were transferred into a flacon 
tube and the cleavage cocktail was added and left shaking for 2h: 96% TFA, 2.5% H2O, 
1.5% triisopropyl silane. The resin was filtered, washed with CH2Cl2, and the filtrate 
concentrated under reduced pressure. The peptides were then precipitated in cold Et2O 
and the precipitate purified by prep-HPLC. 
Semi-preparative RP-HPLC was performed on an Agilent Infinity 1260 series equipped 
with an MWD detector using a Macherey-Nagel Nucleodur C18 column (10 μm x 21 
x 250 mm at 21 mL/min) and fractions were collected automatically by peak detection 
at the specified wavelength using an Agilent 1260 Infinity preparative-scale fraction 
collector using the following chromatographic system: MeCN and 0.1 % aqueous TFA 
[95% TFA (5 min), linear gradient from 5 to 95% of MeCN (35 min), 95% MeCN (40 
min)] and UV detection at 280 nm for peak collection, while monitoring at the 
additional two wavelengths 220 and 254 nm. Fractions of the pure peptides were 
combined and freeze dried before being used for the assays. 
Analytical RP-HPLC-MS was performed on an Agilent infinity 1260 series equipped 
with a MWD detector using a Macherey-Nagel Nucleodur C18 column (10 μm x 4.6 x 
250 mm) and connected to an Agilent 6130 single quad apparatus equipped with an 
electrospray ionization source using the following chromatographic system. 1 mL/min 
flow rate with MeCN and 0.1 % aqueous TFA [95% TFA (5 min), linear gradient from 
5 to 95% of MeCN (35 min), 95% MeCN (40 min)] and UV detection at 220 nm. 
Peptides with truncated recognition sequences were purified by semi-preparative RP-
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HPLC (Agilent infinity 1260 series, Agilent Technologies) using a Jupiter 300 C4 
column (Phenomenex, 10 μM x 16 x 250 mm at 10 mL/min) and fractions were 
collected automatically by peak detection at 220nm using an Agilent 1260 Infinity 
preparative-scale fraction collector. Solvents were 0.1 % aqueous TFA (solvent A) and 
acetonitrile (solvent B). Gradients used for purification of different peptides were as 
follows:  Peptides GVAWAI, GVAWAIQ and GVAWAIQT, 5% B (5 minutes), linear 
gradient from 5 to 40% B (10 minutes), followed by linear gradient from 40-44% 
acetonitrile (20 minutes); Peptides GVAWAF, GVAWAFQ and GVAWAFQA, 5% B 
(5 minutes), linear gradient from 5 to 41% B (10 minutes),  followed by linear gradient 
from 41-50% acetonitrile (20 minutes); Peptides FSASYSSKPI, FSASYSSKPIQ, 
FSASYSSKPIQT, FSASYSSKPF, FSASYSSKPFQ and FSASYSSKPFQA, 5% B (5 
minutes), linear gradient from 5 to 15% B (10 minutes), followed by linear gradient 
from 15-20% acetonitrile (20 minutes). Fractions containing each peptide of interest 
were pooled, their identity and purity verified by LC-MS and lyophilized for later use.  
 
PDB accession codes: Coordinates have been deposited in the Protein Data Bank, with 
accession codes 5O3X (apo PCY1), 5O3W (PCY1-S562A mutant bound to PresegA1 
peptide), 5O3V (PCY1-S562A mutant bound to PresegB1 peptide), and 5O3U (PCY1-
S562A mutant bound to PresegF1 peptide). 
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The Supporting Information containing substrates used, LigPlot, additional ITC and x-
ray crystallography figures is available free of charge on the ACS Publications website.  
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Tables 
 
Table 1. Kinetic parameters for PCY1. 
Substrate Km (µM)       kcat (s-1) kcat/Km (s-1 
M-1) 
Method 
PresegB1 0.45 ± 0.17* 0.37 ± 0.02 820,000 LC/MS  (UV280 nm) 
PresegB1 0.25 ± 0.01 0.14 ± 0.01 560,000 ITC 
PresegF1 2.4 ± 0.5 0.12 ± 0.01 50,000 LC/MS (ion count) 
FSASYSSKP 
FQA 
83 ± 18 0.1 ± 0.01 1,200 LC/MS (ion count) 
FSASYSSKP 
IQT 
227 ± 166 0.016 ± 0.001 70 LC/MS (ion count) 
 
 
Table 2: Binding parameters of PCY1:s562A and various peptides obtained by ITC. 
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Peptide N 
(sites) 
Kd 
(µM) 
Δ H 
(kcal/mol) 
Δ G 
(kcal/mol) 
-T Δ S 
(kcal/mol) 
PresegA1 
1 
0.173 
± 
0.027 
-10.0 ± 0.1 -9.23 0.81 
PresegB1 
1 
0.238 
± 
0.022 
-12.3 ± 0.1 -9.04 3.25 
PresegD1 
1 
0.250 
± 
0.039 
-6.8 ± 0.1 -9.01 -2.19 
PresegF1 
1 
0.136 
± 
0.019 
-11.4 ± 0.1 -9.37 2.03 
PresegA1-NH2 
1 
12.1 
± 2.0 
-5.3 ± 0.2 -6.71 -1.41 
FSASYSSKPIQT 
1 
56.0 
± 
76.5 
-2.8 ± 3.1 -5.90 -3.14 
DNASAPV 
1 
9.58 
± 
0.58 
-14.5 ± 0.2 -6.85 7.64 
NASAPV 
1 
25.2 
± 1.2 
-14.0 ± 0.1 -6.27 7.70 
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Figure legends 
Figure 1: Reaction scheme of macrocyclization catalyzed by PCY1 and sequence 
alignment of presegetalins. a) amino acid one letter code is used to abbreviate amino 
acids, not depicted with the chemical formula. Transparent red circle is highlighting the 
peptide bond formed via macrocyclization. b) Red dots highlight end of core sequence. 
Sequence identity is highlighted with a gradient from white to blue. Deep blue showing 
highest sequence identity. 
 
Figure 2: Kinetic analysis of macrocyclization catalyzed by PCY1. 
a) Comparative time course of PresegA1 (green), PresegB1 (blue) and PresegF1 (red) 
formation with PCY1. Data were fitted mono exponentially. b) LC/MS based steady 
state kinetics of PresegF1 with PCY1 using ion count quantification and product 
calibration curve, fitted non exponentially. c) LC/MS based steady state kinetics of 
PresegB1 with PCY1 using quantification with UV at 280 nm, fitted non exponentially. 
d) Single injection ITC steady-state kinetics of PresegB1, fitted non exponentially. 
Reaction temperature for all experiments: 30 °C 
 
Figure 3: Binding studies of PCY1:S562A and presegetalins. 
Structure of PCY1:S562A bound to PresegF1. PCY1:S562A is drawn in cartoon style, 
-helices are colored orange, -sheets are colored metallic blue and loops are colored 
in light grey. PresegF1 is shown as ball-and-stick model in dark red. Nitrogen atoms 
are colored in blue and oxygen atoms are colored in light red. 2Fo-Fc electron density 
map is shown in mesh style (in blue) and rendered at s: 1.0. a) Overview of the structure 
with peptide shown in spheres showing details into peptide binding site. b) Interactions 
between PresegF1 C-terminus and PCY1:S562A, depicting interactions between the 
peptide carboxylic acid and the enzyme -helix. c) Overlay between complex 
structures, peptides are shown as ball-and-stick model and colored green (PresegA1), 
blue (PresegB1) and red (PresegF1). Figure was adapted from Ligplot47, and additional 
figures depicting interactions with the peptide ligand are available in the supporting 
information.  
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Figure 4: Structural analysis of PCY1:S562A complex structures. 
a) ITC curves showing equilibrium binding measurements for PresegA1 and PresegA1-
NH2 with PCY1:S562A. b) Thermodynamic parameters derived from equilibrium 
binding experiments for a selection of presegetalins. c) Chemical structure of PresegA1 
variants. 
 
 
Figure 5: Expanding the substrate scope of PCY1. Native cyclic peptides (blue), 
cyclic peptides containing non-amino acids and non-native sequences produced by 
PCY1 via macrocyclization. 
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Figure 1 
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Figure 5 
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